Extraesophageal reflux: The role in laryngeal disease

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 10, Issue 6, 2002, Pages 485-491

  Powitzky, Eric S ^a  

^a Center for ENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

AMBULATORY MONITORING; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EXTRAESOPHAGEAL REFLUX; GASTROESOPHAGEAL REFLUX; HUMAN; LAPAROSCOPIC SURGERY; LARYNGOSCOPY; LARYNX DISORDER; PATHOPHYSIOLOGY; PATIENT SELECTION; PH MEASUREMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; STOMACH FUNDOPLICATION;

EID: 0036893527     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/00020840-200212000-00013     Document Type: Review

References (54)

1. Wong RK, Hanson DG, Waring PJ, et al: ENT manifestations of gastroesophageal reflux. Am J Gastroenterol 2000, 95:S15-S22.
2. Eubanks TR, Omelanczuk P, Hillel A, et al: Pharyngeal pH measurements in patients with respiratory symptoms before and during proton pump inhibitor therapy. Am J Surg 2001, 181:466-470. The authors document the efficacy of double, standard dose proton pump inhibitors in the reduction of pharyngeal reflux with pH monitoring after 3 months of therapy. Symptoms resolved in 89% (8 of 9) of patients with suppressed pharyngeal reflux. Four patients (75%) without pharyngeal reflux on pH monitoring were treated in an identical fashion because of their symptoms and results of the laryngeal examination. Three of four (75%) had persistent symptoms despite the same therapy.
3. Ylitalo R, Lindestad P, Ramel S: Symptoms, laryngeal findings and 24-hour 2 site pH monitoring in patients with suspected gastroesophago-pharyngeal reflux. Gastroenterol 2001, 120:A426.
4. Fouad YM, Katz PO, Hatlebakk JG, et al: Ineffective esophageal motility: The most common motility abnormality in patients with GERD-associated respiratory symptoms. Am J Gastroenterol 1999, 94:3658.
5. Postma GN, Tomek MS, Belafsky PC, et al: Esophageal motor function in laryngopharyngeal reflux is superior to that in classic gastroesophageal reflux disease. Ann Otol Rhino Laryngol 2001, 110:1114-1116.
6. Ulualp SO, Gu C, Toohill RJ, Shaker R: Loss of secondary esophageal peristalsis is not a contributory pathogenic factor in posterior laryngitis. Ann Otol Rhinol Laryngol 2001, 110:152-157.
7. Axford SE, Sharp N, Ross PE, et al; Cell biology of laryngeal epithelial defenses in health and disease: Preliminary studies. Ann Otol Rhinol Laryngol 2001, 110:1099-1108.
8. Ren J, Xie P, Lang IM, et al: Deterioration of the pharyngo-UES contractile reflex in the elderly. Laryngoscope 2000, 110:1562-1566.
9. Koufman JA: The otolaryngologic manifestations of gastroesophageal reflux: A clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991, 101(Suppl 53):1-78.
10. Benini L, Ferrari M, Sembenini C, et al: Cough threshold in reflux esophagitis: Influence of acid and of laryngeal and esophageal damage. Gut 2000, 46:762-767.
11. Richter JE: Gastroesophageal reflux disease and asthma: The two are directly related. Am J Med 2000, 108(Suppl 4a):153S-158S.
12. Bowery DJ, Peters JH, DeMeester TR: Gastroesophageal reflux disease in asthma: Effects of medical and surgical antireflux therapy on asthma control. Ann Surg 2000, 231:161-172.
13. Ylitalo R, Ramel S: Extraesophageal reflux in patients with contact granuloma: A prospective controlled study. Ann Otol Rhinol Laryngol 2002, 111:441-446.
14. Maronian NC, Azadeh H, Waugh P, et al: Association of laryngopharyngeal reflux disease and subglottic stenosis. Ann Otol Rhinol Laryngol 2001, 110:606-612.
15. Loughlin CJ, Keufman JA, Averill DB, et el: Acid Induced Laryngospasm in a Canine Model. A Web site publication from The Center For Voice Disorders of The Wake Forest University.edu/voice/dogspasm.html. Accessed June 20, 2002.
16. Maceri DR, Zim S: Laryngospasm: An atypical manifestation of severe gastroesephageal reflux disease. Laryngoscope 2001, 111:1976-1979.
17. Adams J, Heintz P, Gross N, et al: Acid/pepsin promotion of carcinogenesis in the hamster cheek pouch. Arch Otol Head Neck Surg 2000, 126:405-409.
18. Offman JJ: The relation between gastroesophageal reflux disease and esophageal and head and neck cancers: A critical appraisal of the epidemiologic literature. Am J Med 2001, 111:124S-129S.
19. Schweinfurth JM, Powitzky ES, Ossoff RH: Regression of laryngeal dysplasia after serial microflap excision. Ann Otol Rhinel Laryngol 2001, 110:811-814.
20. Heavner SB, Hardy SM, White DR, et al: Transient inflammation and dysfunction of the eustachian tube secondary to multiple exposures of simulated gastroesephageal refluxant. Ann Otol Rhinol Laryngol 2001, 110:928-934.
21. Tasker A, Dettmar P, Benckiser R, et al: Does gastro-esophageal reflux have a role in otitis media with effusion? Gastroenterology 2001, 120:A-119.
22. Ulualp SO, Toohill RJ: Laryngopharyngeal reflux: State of the art diagnosis and treatment. Otolaryngol Clin North Am 2000, 33:785-801.
23. Ylitalo R, Lindestad P, Ramel S: Symptoms, laryngeal findings and 24-hour pH monitoring in patients with suspected gastroesophago-pharyngeal reflux. Laryngoscope 2001, 111:1735-1741. A prospective study of consecutive patients with suspected EER, patients with posterior laryngitis, and normal control subjects. The authors note that some reflux does occur in control subjects with normal examination findings, that symptoms alone are unreliable, and that physical findings do not predict abnormal pH study results. The importance of pharyngeal pH monitoring is discussed.
24. Noordzij JP, Khidr A, Evans BA, et el: Evaluation of omeprazole in the treatment of reflux laryngitis: A prospective, placebo-controlled, randomized, double-blind study. Laryngoscope 2001, 111:2147-2151. A prospective, randomized, placebo-controlled, double-blind trial comparing double, standard dose omeprazole for 8 weeks to placebo. Interestingly, many of the "classic" symptoms of EER improved in both groups, indicating a significant placebo effect. Alternative explanations for the findings provide an excellent outline of the inherent limitations in the study of EER.
25. Eubanks TR, Omelanczuk PE, Maronian N, et al: Pharyngeal pH monitoring in 222 patients with suspected laryngeal reflux. J Gastrointest Surg 2000, 52:183-190.
26. Belafsky PC, Postma GN, Koufman JA: The validity and reliability of the reflux finding score. Laryngoscope 2001, 111:1313-1317.
27. Belafsky PC, Postma GN, Koufman JA: Laryngopharyngeal reflux symptoms improve before changes in physical findings. Laryngoscope 2001, 111:979-981. An important study outlining the expected time course of change in the laryngeal examination of patients with EER. Symptoms improved over the first 2 months of therapy with proton pump inhibitors while the changes in physical findings continue to 6 months, and perhaps beyond 6 months. The authors conclude that proton pump inhibitor therapy should continue for a minimum of 6 months while laryngeal inflammation subsides.
28. Branski RC, Bhattaacharyya N, Shapiro J: The reliability of the assessment of endoscopic laryngeal findings associated with laryngopharyngeal reflux disease. Laryngoscope 2002, 112:1019-1024. The reliability of the video laryngeal examination in the diagnosis of EER is evaluated. The authors note significant inter-rater and intrarater variability in the analysis of video laryngeal examination results in suspected EER patients. They note that despite variability for individual signs, the raters were consistent with respect to the complete examination and to which patients warranted treatment.
29. Koufman JA: Gastroesophageal reflux and voice disorders. In Diagnosis and Treatment of Voice Disorders. Edited by Rubin JS, Sataloff RT, Korovin GS, Gould WJ. New York-Tokyo: Igaku-Shoin Publishers; 1995:161-175.
30. Hickson C, Simpson CB, Falcon R: Laryngeal pseudosulcus as a predictor of Laryngopharyngeal reflux. Laryngoscope 2001, 111:1742-1745.
31. Khaitan L, Powitzky ES, Cohen J, et al: Is one episode enough? Gastroenterology 2001, 101:531.
32. Smit CF, Tan J, Devriese PP, et al: Ambulatory pH measurements at the upper esophageal sphincter. Laryngoscope 1998, 108:299-302.
33. Vincent DA, Garrett JD, Radionoff SL, et al: The proximal probe in esophageal pH monitoring: Development of a normative database. J Voice 2000, 14:247-254.
34. Postma GN: Ambulatory pH monitoring methodology. Ann Otol Rhinol Laryngol 2000, 109(suppl 184):10-1434.
35. Panetti M, ReVille J, Clyne S, et al: Clinical implications of the functional stability of pepsin. Presented at the Annual Meeting of the American Academy of Otolaryngology-Head Neck Surgery, San Antonio, Texas, September 1998.
36. Kammer P, Dahlke J, Rhoten D, et al: Patient acceptability of prolonged pH testing. Gastroenterology 2001, 120:A427.
37. Johnson PE, Koufman JA, Nowak LJ, et al: Ambulatory 24-hour double probe pH monitoring: The importance of manometry. Laryngoscope 2001, 111:1970-1975.
38. Eubanks TR, Omelanczuk PE, Maronian N, et al: Pharyngeal pH monitoring in 222 patients with suspected laryngeal reflux. J Gastrointest Surg 2000, 52:183-190.
39. Vaezi MF, Richter JE: Duodenogastroesophageal reflux and methods to monitor nonacidic reflux. Am J Med 2001, 111(Suppl 8A):160S-168S.
40. Hatlebakk JG, Katz PC, Kuo B, et al: Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Ailment Pharmacol Ther 1998, 12:1235-1240.
41. Harding SM, Richter JE, Guzzo MR, et al: Asthma and gastroesophageal reflux: Acid suppressive therapy improves asthma outcome. Am J Med 1996, 100:395-405.
42. Ours TM, Kauvuru MS, Schilz RJ, et al: A prospective evaluation of esophageal testing and a double-blind, randomized study omeprasole in a diagnostic and therapeutic algorithm for chronic cough. Am J Gastroenterol 1999, 94:3134-3138.
43. Wo JM, Grist WJ, Gussack G, et al: Empiric trial of high dose omeprazole in patients with posterior laryngitis: A prospective study. Am J Gastroenterol 1997, 92:2160-2165.
44. Shaw GY, Searl JP, Young JL, et al: Subjective, laryngoscopic, and acoustic measurements of laryngeal reflux before and after treatment with omeprazole. J Voice 1996, 10:410-418.
45. Havas T, Huang S, Levy M, et al: Posterior pharyngolaryngitis: Double-blind, randomized placebo-controlled trial of proton pump inhibitor therapy. Aust J Otolaryngol 1999, 3:243-246.
46. Amin MR, Postma GN, Johnson P, et al: Proton pump inhibitor resistance in the treatment of laryngopharyngeal reflux. Otololaryngol Head Neck Surg 2001, 125:374-378.
47. Katz PO, Anderson C, Khoury R, et al: Gastro-esophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Ailment Pharmacol Ther 1998, 12:1231-1234.
48. Katz PO: Medical therapy of extraesophageal gastroesophageal reflux disease. J Clin Gastroenterol 2000, 30(Suppl 3):S42-44.
49. Bowery DJ, Peters JH, DeMeester TR: Gastroesophageal reflux disease in asthma: Effects of medical and surgical antireflux therapy on asthma control. Ann Surg 2000, 231:161-172.
50. DeVault KR: Overview of therapy for the extraesophageal manifestations of gastroesophageal reflux disease. Am J Gastroenterol 2000, 95(suppl 8):S39-S44.
51. Irwin R, Richter J: Gastroesophageal reflux and chronic cough. Am J Gastroenterol 2000, 95(Suppl 8):S9.
52. Fernando HC, Schauer PR, Rosenblatt M, et al: Quality of life after antireflux surgery compared with nonoperative management for severe gastroesophageal reflux disease. J Am Coll Surg 2002, 194:23-27.
53. Richards WO, Scholz S, Khaitan L, et al: Initial experience with the Stretta procedure for the treatment of gastroesophageal reflux disease. J Laparoendosc Adv Surg Tech 2001, 11:267-273.
54. Triadafilopoulos G, DiBaise JK, Nostrant TT, et al: The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial. Gastrointest Endosc 2002, 55:149-156.